Back to Search Start Over

Targeted liposomes for macrophages-mediated pulmonary fibrosis therapy.

Authors :
Wang, Yujie
Zhao, Fang
Wang, Xiangyu
Zuo, Haojie
Ru, Yiming
Cao, Xi
Wang, Yang
Source :
Drug Delivery & Translational Research; Sep2024, Vol. 14 Issue 9, p2356-2369, 14p
Publication Year :
2024

Abstract

Pulmonary fibrosis (PF) is a horrible lung disease that causes pulmonary ventilation dysfunction and respiratory failure, severely impacting sufferers' physical and mental health. Existing drugs can only partially control the condition and are prone to toxic side effects. Anti-inflammatory treatment is the committed step to alleviate PF. Celastrol (CLT) has significant anti-inflammatory effects and can reverse M1-type transformation of macrophages. In this study, we have developed liposomes loaded with CLT, modified with folate (FA), designated FA-CLT-Lips, which facilitate drug delivery by targeting macrophages. FA-CLT-Lips were shown to be more readily absorbed by macrophages in vitro and to encourage the transition of M1 macrophages into M2 macrophages. In addition, FA-CLT-Lips can inhibit the phosphorylation of Smad2/3, effectively reducing the deposition of extracellular matrix (ECM) and the production of inflammatory factors. This showed that FA-CLT-Lips can ameliorate early lung fibrosis by lowering inflammation. In vivo studies have shown that FA-CLT-Lips accumulate in lung tissue to better attenuate lung injury and collagen deposition, with less toxicity compared to free CLT. In summary, FA receptor-targeting liposomes loaded with CLT provide a secure and reliable PF therapy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
2190393X
Volume :
14
Issue :
9
Database :
Complementary Index
Journal :
Drug Delivery & Translational Research
Publication Type :
Academic Journal
Accession number :
178777220
Full Text :
https://doi.org/10.1007/s13346-023-01508-3